By Harjott Atrii and Umesh Kuppuraj Over the past year, we have seen a growing pattern across MedTech and pharmaceutical organizations. Many are moving quickly to adopt AI, but too many are doing so through a marketplace mindset. They are buying access to tools, models, and platforms that promise speed, while postponing the harder question of ownership. In my view, that is where the real strategic issue lies. For regulated industries, AI is not just another software layer.